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Dengue virus infection is a serious health problem infecting 2.5 billion people worldwide. Dengue is now endemic
in more than 100 countries, including Pakistan. Each year hundreds of people get infected with dengue in Pakistan.
Currently, there is no vaccine available for the prevention of Dengue virus infection due to four viral serotypes.
Dengue infection can cause death of patients in its most severity, meanwhile many antiviral compounds are being
tested against dengue virus infection to eradicate this disease but still there is a need to develop an efficient,
low-cost and safe vaccine that can target all the four serotypes of dengue virus. This review summarizes dengue
molecular virology, important drug targets, prevalence in Pakistan, diagnosis, treatment and medicinal plant
inhibitors against dengue.
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Dengue virus (DENV) infection is an important
arthropod-born viral infection infecting about 2.5 billion
people worldwide, of which approximately 975 million
belong to large and small cities of tropical and sub-
tropical countries in Southeast Asia, the Pacific and the
America [1, 2]. The prevalence of dengue has grown
dramatically in recent decades and is now endemic in
more than 100 countries [3]. Approximately, 50 to 100
million infections occur each year leading to 500,000
hospitalizations and 20,000 deaths, estimated by WHO
[4]. Dengue virus was first isolated from Japan in 1942
by Hotta [5]. Dengue virus belongs to Flaviviridae family
and is transmitted to humans by infective female of
Aedes genus, especially Aedes aegypti or Aedes albopic-
tus mosquito [6, 7]. There are 4 related, but antigenically
distinct serotypes of dengue virus (DEN 1–4) evolved
from a common ancestor who manifest with similar
symptoms [8, 9]. Dengue virus causes two types of infec-
tions, primary infection and secondary infection. Pri-
mary infection results in acute febrile illness known as
dengue fever (DF) which is cleared in approximately
seven days by a complex immune response. Secondary
infection is more severe and results in haemorrhagic* Correspondence: usmancemb@gmail.com
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distribution, and reproduction in any mediumfever (DHF) or dengue shock syndrome (DSS) [10]. Pre-
dominantly, it affects children in Southeast Asia and is
characterized by increased vascular permeability, plasma
leakage, haemorrhagic manifestations and thrombo-
cytopenia. Both DHF and DSS can be fatal and can lead
to death among the patients [11]. Pakistan due to its
crowded cities, unsafe water, inadequate sanitation, large
number of refugees and low vaccination coverage is at
high risk of dengue endemics. [12]. To date, there is no
vaccine available to combat dengue infection. The vac-
cine must be tetravalent to be effective in all four sero-
types and there is no efficient animal model available for
DHF/DSS. Therefore, developing vaccine against dengue
is quite challenging. Dengue is a life-threatening fever
that can cause death of patients in its most severity, cur-
rently many antiviral compounds are being tested against
dengue virus infection to eradicate this disease but still
there is a need to develop an efficient, low-cost and safe
vaccine that can target all the four serotypes of dengue
virus.DENV life cycle
To date, many research studies have been conducted to
understand the life cycle of dengue virus, especially the
viral protein processing and the genome replication.
Dengue virus binds to its receptor, and this process is
mediated by envelop protein (E). In mammalian cell,ntral Ltd. This is an Open Access article distributed under the terms of the
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DC-SIGN/L-SIGN and Mannose receptors. DEN-2 sero-
type also binds with HSP70/HSP90, GRP78, CD14-
associated protein and two unknown proteins having
trypsin resistance and trypsin sensitive properties. DEN
1–3 serotypes as well bind with Laminin receptor. DEN
2–4 serotypes also bind with an unknown protein having
the property of serotype specific binding (Figure 1) [13].
After initial attachment of the virus with particular
receptors on the surface of host cell, the viral particle is
fused into acidic lysosomes through receptor-mediated
endocytosis. After that, viral particle is uncoated and the
RNA is released in host cell where it directs the synthe-
sis of viral proteins (Figure 2). Once all the essential pro-
teins are synthesized, viral RNA starts copying to
generate a minus strand, which is then transcribed to
new plus stranded molecules. In only few hours after in-
fection, tens of thousands copies of viral molecules are
produced from a single viral molecule leading to cell
damage and in severe cases to death. Viral-encoded
RNA-dependent RNA polymerases (RdRps) and other
cellular factors are responsible for catalyzing the infec-
tion cycle of dengue virus [14]. The mechanism of vas-
cular permeability and haemorrhaging is not clearly
known. To understand these mechanism studies are
being focused on the role of T-cell immune response.
After 1–2 days of onset fever during secondary infection,
high concentrations of interferon alpha were recorded
[15]. High concentrations of soluble interleukin 2 recep-
tor, soluble CD4, soluble CD8, interleukin 2, and inter-
feron γ were also studied during the onset of vascular
permeability [16].
DENV genome
Dengue virus is plus stranded RNA virus with genome of
11 kilobases. The dengue virus genome with a large open
reading frame encodes a polyprotein precursor of about
3000 amino acids that are processed cotranslationally andFigure 1 DENV cell entry receptors.posttranslationally by viral and host proteases. This poly-
protein precursor is cleaved to generate at least 10 pro-
teins like other viruses belonging to Flaviviridae family
[17]. These proteins include three structural proteins, nu-
cleocapsid or core protein (C), a membrane associated
protein (M), an envelope protein (E) and seven nonstruc-
tural proteins. The order of genes is in 5_-CprM (M)-E-
NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3 (Figure 3) [18].
These viral proteins are responsible for viral replication
and various cellular functions [19]. Viruses upon infection
activates interferon (IFN) signaling pathway but dengue
develops interferon resistance. NS2a, NS4a and NS4b
block the interferon cascade to escape the immune re-
sponse. NS4b inhibits interferon cascade by blocking
STAT-1 phosphorylation [17].
DENV proteins and therapeutic targets
DENV structural proteins
DENV has three structural proteins: Core protein (C), a
membrane associated protein (M) and Envelop protein
(E). These proteins are involved in defining the structure
of the virus.
DENV core protein (C)
DENV core protein is a highly basic protein responsible
for assembly of nucleocapsid through interaction with
RNA but only a little is known about C protein. Struc-
ture of the protein revealed that the C protein dimer
had high net charge and there is asymmetric distribution
of basic residues over the surface of protein [20]. Anti
DEN-2 core protein monoclonal antibodies (MAbs)
reacted with antigens in cytoplasm and in the nucleus of
DEN-2 and DEN-4 but not DEN-1 and DEN-3. These
MAbs also reacted with core proteins of DEN-1, DEN-2
and DEN-4 in western blot studies. All MAbs react with
region (9RNTPFNMLKRE19) of DEN-2 core protein
revealed by PEPSCAN epitope mapping [21]. The core
protein C localizes in nucleus. It was determined that a
Figure 2 Dengue virus replication cycle.
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sponsible for the nuclear localization of the core protein
and without this motif core protein resides in the cyto-
plasm of DEN-infected cells [22].
Membrane associated protein (M)
Membrane associated protein is a membrane glycopro-
tein works as a part of nucleocapsid and assists to en-
velop protein to form mature virions. Antibodies against
prM protein were developed for Japanese encephalitis
virus (JEV), West Nile virus (WNV) and dengue virus.
Antibodies against the prM protein of JEV do not react
with the prM of dengue viruses or West Nile virus. prMFigure 3 Dengue virus genome. Dengue virus genome encodes 10 viral
viral structure and viral attachment to host cell and 7 non-structural protein
replication and other cellular function.protein can be used to investigate differentiating anti-
body responses to difference flaviviruses [23]. C-prM
was first identified by immuno-precipitating the Aedes
albopictus cells infected with DEN-2. These cells were
cleaved to produce membrane associated protein (M)
and non membrane fragment (pr). This cleavage was less
efficient in mosquito cells. Proteins containing fragment
was then fused with staphylococcal protein A. The fused
protein was stable and were used to generate antisera in
rabbits [24]. The E-prM interactions in dengue virus are
mediated by domains in the carboxy-terminal anchoring
domain of E, while cell activity is mediated by trypsin-
releasable ectodomain of E protein [25].proteins including 3 structural proteins (C, M, and E) responsible for
s (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) that are involved in viral
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Envelop protein is present on the surface of the virus
and is extremely involved in virus attachment with host
cell through cell receptors like heparin sulphate DC-
SIGN. It is most important protein for the entry of virus
in cell. This protein has three domains, domain I (struc-
tural domain), domain II (dimmers) and domain III
(binding domain). Dimmer domain links structural and
binding domain [26, 27]. The Dengue virus enters a host
cell when viral envelop protein binds to receptor and
responds by conformational rearrangement to the
reduced pH of an endosome. The conformational
change induces fusion of viral and host-cell membranes
[28]. Flaviviruses uses a fusion mechanism by inserting
distal β barrels of domain II of E protein into cellular
membrane [29]. Crystal structure of soluble ectodermal
domain of E revealed a hydrophobic pocket lined by
residues that influence the pH for fusion. This pocket
opens and closes in the β-hairpin at the interface be-
tween two domains. Thus, it can be used to test antiviral
compounds [30].
DENV non-structural proteins
DENV genome encodes seven non-structural proteins,
including NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5.
These proteins are responsible for viral replication and
other cellular functions.
NS1 protein
NS1 is expressed on the surface of the infected cell and
can serve as an antibody target for dengue infection [31].
NS1 protein is involved in RNA replication as it resides to
site of RNA replication but still the role of NS1 is unclear.
NS1 Antigen was detected from the 1st day to day 9 of in-
fection. This was even detected when viral RNA was nega-
tive in RT-PCR. Its level differed in individuals ranging
from a couple of nanograms per milliliter to several
micrograms per milliliter. Thus, detection of NS1 protein
may allow diagnosis of dengue infection in early stages
[32]. In a study, plasma level of secreted NS1 (sNS1) were
measured in 32 children infected with DEN-2. sNS1 level
was higher in patients with DHF than DF. Within,
72 hours of infection, sNS1 level was ≥600 ng/mL indicat-
ing the risk of developing DHF [33]. NS1 mediated com-
plement activation leads to generation of SC5b-9, may be
involved in vascular leakage in DHF/DSS patients [34].
NS2A protein
NS2A protein is majorly involved in RNA replication
and viral assembly. A mutation in NS2A protein blocked
virus replication. NS2A also inhibits the IFN-β pro-
moter-driven transcription, thus serves as interferon
(IFN) antagonist [17, 35]. A single amino acid mutation
in NS2A was identified that reduces inhibitory activity ofNS2 [35] . NS2A may be a cis-acting protease that
cleaves itself from NS1 protein or may provide recogni-
tion sequences to cellular proteases that cleaves their
junction [36]. NS2A were found to be located in discrete
foci in the cytoplasm at 16 and 24 hours pos-infection
[37]. Using KUN replicon vectors for gene expression
NS2 has been identified as new target for developing live
flavivirus vaccines [35].
NS2B protein
NS2B works as a cofactor in NS2B-NS3 serine protease.
NS2B is required for the cleavage of NS2A/NS2B and
NS2B/NS3.NS2B is also required for NS3/NS4A cleav-
age and for other internal cleavages [38].Wang and col-
leagues investigated the extent of intra host sequence
variation of NS2B, derived from plasma dengue viruses
from 18 DEN-3 infected patients. They demonstrated
the quasi species structure of dengue virus in-vivo and
suggested that sequence variation in DEN-3 NS2B was
likely to reflect genetic drift [39]. Falgout and colleagues
determined a 40 amino acid segment of NS2B (DEN4
amino acids 1396 to 1435) essential for protease activity.
This segment constitutes a hydrophilic domain sur-
rounded by hydrophobic regions. The hydrophilic do-
main of NS2B will prove to be essential for protease
activity [40].
NS3 protein
NS3 of DEN-2 is second largest non-structural protein
having serine protease at N-terminus and NTPase heli-
case RNA triphosphate (RTPase) at C-terminus end.
[41]. NS3 is also involved in RNA replication and helps
in regulating poly protein processing [42, 43]. Teo and
colleagues proposed that NS3 results from cleavage at
site . . .R457R / GR460. . . in RNA helicase sequence
motif, and it does not require prior cleavage of NS2B/
NS3 [43]. NS3 was immune-dominant in CD4+ T-cell
response of DEN-3 infected donor [44]. Immunoblotting
and coimmunoprecipitation studies showed that NS3
protein also interacts with NS5 protein in DEN-2
infected monkey kidney cells and HeLa cells co-infected
with a recombinant vaccinia virus [45].Chow and collea-
gues studied NS3 gene targets of all four dengue sero-
types using RT-PCR followed by ELISA. The results
were high spectrophotometric absorbance obtained by
hybridization consensus amplification products with
their probe [46]. Non substrate based inhibitors have po-
tency to bind in the P1 subpocket of catalytic site of
DENV NS3 protease [47]. Recently, the release of 3D
structure of NS2B, NS3 of DEN-2 has opened new ways
to discover potent antiviral compounds that can target
all four dengue serotypes [48]. Due to recent availability
of NS3 helicase 3D structure, it was discovered that
RTPase uses helicase scaffold to perform their activity
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replication are considered to be an important drug tar-
get against dengue virus infection. But still there is a
need to develop antiviral compounds that can target all
four serotypes of dengue with same efficiency. Evalu-
ation work of NS3 domains from all four serotypes is
currently in progress.
NS4A protein
NS4A is the least characterized protein. At its C-
terminus end, it is highly hydrophilic and serves as a sig-
nal to translocate NS4B to the endoplasmic reticulum
lumen. In membrane bound viral replication complex
(RC), NS4A forms components that help in maintaining
this complex [50]. NS4A has a role in replication cycle,
membrane rearrangements and their regulation. The N-
terminus of NS4A is generated by cleavage by viral pro-
teinase NS3 in a cell-free system [51]. NS4A is located
in discrete foci in the cytoplasm of infected cell at both
16 and 24 hours of post-infection, partially coincident
with dsRNA foci [37].
NS4B protein
NS4B interacts with NS3 to regulate RNA replication.
When treated with IFN-β or IFN-γ, NS4B expressing
cells did not exhibit signal transducer and activator of
transcription (STAT 1), thus indicated that NS4B may
be involved in blocking IFN signaling and can be impli-
cated as IFN-signaling inhibitor [17]. Function of NS4B
is conserved in West Nile and yellow fever viruses. First,
125 amino acids of dengue virus NS4B is sufficient for
inhibition of alpha/beta IFN (IFN-α/β) signaling [52].
NS5 protein
NS5 has a methyltransferase (MTase) domain at N-
terminus end and a polymerase domain at C-terminus
end. NS5 has a role in RNA replication due to presence
of RNA dependent RNA polymerase activity. It is also
involved in de novo initiated RNA synthesis [53].
Charge-to-alanine mutagenesis of DEN-4 NS5 gene gen-
erated a collection of attenuating mutations for potential
use in a recombinant live attenuated DEN vaccine [54].
NS5 in the hyper-phosphorylated form does not interact
with NS3 due to action of functional nuclear localization
sequence within the inter domain region of NS5 (resi-
dues 369–405). Importin-β with NS5 has implication for
the mechanism by which this normally cytoplasmic pro-
tein may be targeted to the nucleus [55]. DENV
NS5MTase structure with the co-product methyl trans-
fer S-adenosyl-L-homocystein is a intial step for devel-
oping antiviral drugs against DENV [56]. C-terminal
domain of NS5 possesses RNA-dependent RNA poly-
merase (RdRp) activity that is involved in viralreplication and is an important drug target for discover-
ing new drugs [53].
Prevalence in pakistan
Dengue has a worldwide history of about 200–400 years,
mostly causing infection in tropical and sub-tropical
areas. Dengue virus is believed to come in Pakistan with
tyres at Karachi sea port carrying eggs of infected mos-
quitoes. To date, dengue virus infection has caused sev-
eral outbreaks in Pakistan [57, 58]. Until 1994, there was
no valid data available about dengue infection cases in
Pakistan. In 1982, Dengue was identified in Pakistan,
Punjab. Out of 174 patients, 12 were dengue virus posi-
tive [58]. In 1985, a research was conducted to study the
prevalence of dengue virus infection in Pakistan. It
showed that about 50-60% of the Pakistanis, especially
those living in Karachi were haem agglutination inhib-
ition (HI) antibody positive for West Nile, Japanese en-
cephalitis and DENV-2 Flaviviruses. These cases rapidly
increased from July to October in patients ranging from
6 to 20 year age [59]. In 1994, first outbreak of DHF was
reported in Pakistan [60]. Out of 16 patients, 15 had
dengue IgM identified using DENV2 antigen. It was also
observed that in three out of ten patients of dengue
virus were infected with DEN-1 and DEN-2 [61]. In
1995, DEN-2 infection was reported from Balochistan
[62, 63]. In 1998, DEN-1 and DEN-2 were found in
patients using ELISA study [64]. In 2005, outbreak of
DHF in Karachi, DEN-3 was reported among the few
tested patients. In serum of children in karachi, DEN-1
and DEN-2 were found using serological studies [64,
65]. DEN-2 and DEN-3 were found to be co-circulated
during 2006 outbreak in Karachi [57, 66]. DEN-3 in
2006 outbreak in Pakistan was found to be closely
related to DEN-3 in 2004 outbreak in New Delhi [67]. In
2008, a dengue outbreak was reported in Lahore infect-
ing a large number of citizens of Lahore. Samples were
found to have DEN-4, DEN-2 and DEN-3 infection [63].
In 2009, it was reported that children living in Karachi
had high levels of anti-dengue IdM antibody [68]. Sam-
ples had concurrent infection with serotypes DEN-2 and
DEN-3. Studies showed that serotype DEN-2 was dom-
inant in samples of dengue virus infection collected dur-
ing the period of three years (2007–2009) [7]. In
November 2010, it was reported by a private news chan-
nel that Out of the 5,050 patients, 2,350 patients were
from Sindh, 1,885 from Punjab and at 158 patients from
Khyber Pakhtunkhwa [69].The samples had an infection
with DEN-2 and DEN-1 (Table 1) [70].
During 2011, the disease rapidly assumed the propor-
tions of epidemic, specifically in Punjab and particularly
Lahore where, in September, more than 250 people were
reported dead and, according to the Punjab Health De-
partment, over 12,000 people were infected during
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dengue virus. According to the Sindh Provincial Dengue
Surveillance Cell, nearly 400 people were infected with
the virus in few months with over 300 people in Karachi
alone, and the death toll stood at five at the end of
September 2011. In February 2012, 73 confirmed cases of
dengue in Lahore and 13 other regions of the state of Pun-
jab were reported (http://www.paperpk.com/news/index.
php/new-dengue-cases-punjab-2012/). The year 2007 and
2011 has been worst years in regard of dengue virus in-
fection in Pakistan. Dengue virus circulates in Pakistan
throughout the year with a peak incidence in the post
monsoon period. Recent flood in Pakistan made the
situation worse [12].
Diagnosis
Dengue virus can cause mild fever to Dengue fever (DF)
or more severely DHF/DSS. DF causes fever in 3–5 days
of infection, in which patient can feel headache, joint pain
and rashes on the body with thrombocytopenia and rela-
tive leucopenia. Both DHF and DSS have same symptoms
as of DF but they also have increased vascular permeabil-
ity and hemorrhage, can lead to death. Dengue infection is
mostly clinically diagnosed through symptoms. However,
diagnosing dengue infection through symptoms is not reli-
able, and it needs laboratory studies to confirm the pres-
ence of dengue virus [71, 72]. Differential diagnosis is also
important because dengue fever can easily be confused
with non-dengue illnesses, particularly in nonepidemic
situations. Depending on the geographical origin of the
patient, other etiologies, including non-dengue flavivirus
infections should be ruled out.
Laboratory diagnosis of dengue virus infection can be
made by the detection of particular virus, viral antigen,
genomic sequence, and/or antibodies. IgM captured
ELISA, virus isolation in mosquito cell lines and live mos-
quitoes, dengue specific monoclonal antibodies and detec-
tion of viral RNA by nucleic acid amplification tests
(NAAT) have all represented major advances in dengue
diagnosis. There are two stages of diagnosing dengueTable 1 Year-wise prevalence of dengue virus serotypes
in Pakistan
Year DENV Serotype Reference
1994 DEN-2 [61]
1995 DEN-2 [62, 63]
1998 DEN-1, DEN-2 [64]
2005 DEN-1, DEN-2, DEN-3 [64, 65]
2006 DEN-2, DEN-3 [57, 66]
2008 DEN-2, DEN-3, DEN-4 [63]
2009 DEN-2, DEN-3 [7]
2010 DEN-1, DEN-2 [70]infection. In stage 1, fever is accompanied by NS1 antigens
in blood and in the stage 2, post-febrile period in which
IgM and IgG antibodies are in excess. In acute phase of
dengue, patients generally suffer from flu-like fever and
seek medical attention in first two days. During this phase,
diagnosis is possible by detecting viral RNA/proteins in
patient blood. If after two days fever is not recovered, then
patient should be advised for a complete blood checkup
(CBC). After the checkup, if platelet count is below nor-
mal range (150,000 to 450,000 platelets per microliter of
blood), and WBC count is below normal range (4300–
10,800 WBCs per cubic millimeter (cmm) of blood) then
patient should go for dengue antigen test. Patients with
DHF/DSS should go for serological test. Using serotype
specific NS3 primers, infection was identified in 80%
patients [73]. Dengue viral RNA can be detected in early
phase of infection using real-time reverse transcriptase
(RT) PCR. These techniques are reliable in detecting den-
gue virus but are costly [74, 75]. ELISA test using dengue-
specific NS1 monoclonal antibody is being used to detect
NS1 in blood of the patients and to characterize the pri-
mary and secondary infection in patients [76, 77]. MAC-
ELISA assays when combined with NS1 Ag holds promise
to detect the dengue viruses in early phases of infection
[78]. Currently used laboratory methods are: capture ELI-
SAs, immunofluorescence tests, and hemagglutination
assays [79]. A recent study was conducted to use saliva to
detect the dengue virus specific immunoglobulin A (IgA)
in early phase of dengue infection. This technique can be
very helpful in dengue endemic regions, where the major-
ity of dengue cases are secondary[80]. A new diagnostic
test has recently been approved by US Food and Drug ad-
ministration, the CDC DENV-1-4 Real time RT PCR
Assay developed by Centers for Disease Control and Pre-
vention to detect the dengue viruses in infected patients
[81]. However, there is a need to develop an effective and
low cost diagnostic methods that can detect the presence
of dengue virus in acute phase of infection so that clinical
preventive measure can be taken to avoid any severity of
the disease.
Prevention & treatment
To date, there is no specific treatment available for den-
gue virus infection. There are three ways to solve the
problem of dengue infection. The First is to use a pre-
ventive measure by avoiding contact with infected mos-
quitoes. Aedes mosquitoes bite during daytime and its
contact can be avoided by: properly managing waste and
improving storage of water, removing all sources of stag-
nant water, using household pesticides to kill mosqui-
toes, using mosquito coils and nets, wearing long-
sleeved shirts, socks and trousers and using insect
repellent to avoid mosquitoes. Insecticide treated nets
(ITNs) are available to protect young children, pregnant
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during the day [12]. Government of Pakistan and Pun-
jab, Pakistan is working on preventive measure by in-
creasing awareness of dengue among people. Spraying
teams for purpose of fumigation and spraying are orga-
nized to kill Aedes mosquito known to infect people
(http://en.wikipedia.org/wiki/2011_dengue_outbreak_in_
Pakistan). The Second is vaccination, which is currently
not available and the Third is drug therapy but no anti-
viral drugs are available to target dengue virus [82].
However, supportive care and treatment can save a pa-
tient infected with dengue fever. Fever can be treated by
anti-pyretics, like paracetamol. Joint pain can be treated
by analgesics or painkiller tablets. In case of DHF/DSS,
patients must be hospitalized. Dehydration can be pre-
vented by oral rehydration therapy and if oral intake is
imposible then intravenous fluid replacement can be
used to prevent shock in infected patients. If platelet
level drops below 20,000 or if there is significant bleed-
ing, then platelet transfusion is recommended. Drugs
such as aspirin, brufen and non-steroidal anti- inflam-
matory should be avoided as they may worsen the bleed-
ing tendency. Any medicine that decreases the platelet
level should be avoided (http://www.denguevirusnet.
com/treatment.html).
Medicinal plants as dengue virus inhibitors
Plants have been traditionally used to cure a number of
human diseases. To date, few plants derivatives due to
their medicinal properties have successfully been tested
against viral diseases. The first step of DENV cycle is to
attach with host via host receptors. Envelop protein (E)
is involved in viral and host attachment. Thus, dengue
infection can be inhibited by targeting envelop protein/
inhibiting host-viral interactions. NS2-NS3 protease and
NS5 also serve as important antiviral drug targets due to
their role in viral replication and other cellular pro-
cesses. To date, many medicinal plants have been tested
against DENV and some of them showed significant in-
hibition effects in the DENV replication cycle.
Antiviral effects of methanolic extracts of Androgra-
phis paniculata, Citrus limon, Cymbopogan citrates,
Momordica charantia, Ocimum sanctum and Pelargo-
nium citrosum on dengue virus serotype 1 (DENV-1)
were investigated by Tang and colleagues. A. paniculata
showed the most antiviral inhibitory effect followed by
M. chrantia in in-vitro assays. Both these plants can be
advantageous in developing novel antiviral compounds
[83]. Carica papaya contains two important biologically
active compounds, chymopapain and papain, which are
used in digestive disorders [84]. C. papaya leaves extract
prepared in water has been tested against dengue fever.
After the administration of aqueous extract in dengue
infected patient, the platelet count increased from55x103/μL to 168x103/μL, White blood cells from
3.7x103/μL to 7.7x103/μL and neutrophils from 46% to
78%. Thus carica papya can be used to target dengue
fever [85]. Extracts of neem leaves and pure neem com-
pound (Azadirachtin) were tested against DENV-2 repli-
cation. In-vitro activity was assessed in C6/36 (cloned
cells of larvae ofAedesalbopictus) cells. Aqueous neem
extracts at its maximum nontoxic concentration of
1.897 mg/ml, completely inhibited 100–10,000 TCID50 of
virus as indicated by the absence of cytopathic effects
[86]. Talarico and colleagues investigated lambda- and
iota-carrageenans, sulfated polysaccharides containing
linear chains of galactopyranosyl residues against DEN-2,
DEN-3 using Vero and HepG2 cells and found that these
compounds are potent dengue inhibitors. The inhibitory
action was exerted by dual interference with virus ad-
sorption and internalization of nucleocapsid into the
cytoplasm. Carrageenans did not interfere with viral pro-
tein synthesis and virus multiplication. Thus, carragee-
nans can be used in developing new therapies by
interfering with virus adsorption in host cell [87]. Rehman
and colleagues investigated Quercus lusitanica extract
against DEN-2 replication. At a concentration of 180 μg/
ml, Q. lusitanica was found to completely inhibit dengue
virus infection. Furthermore, methyl gallate from fractio-
nalized crude extracts showed 96% inhibition at the
maximum non-toxic dose (MNTD) of 100 μg/mL [88].
DEN-2 infection was inhibited by WSS45 (Sulfate deriva-
tive of an alpha-D-glucan) derived from Gastrodia B1 in
BHK (Baby hamster kidney fibroblast cells) cells with an
EC (50) value of 0.68+/−0.17 μg/mL. WSS45 interfered
with virus adsorption but showed no viricidal effect.
Thus, WSS45 can be used to increase virus detaching
from the host cell surface [89]. Replication of DEN-2 was
significantly reduced by two compounds; 1-beta-d-ribo-
furanosyl-3-ethynyl-[1, 2, 4]triazole (ETAR) and 1-beta-
d-ribofuranosyl-4-ethynyl-[1, 3]imidazole (IM18). ETAR
also reduced replication of DEN-1, DEN-3 and DEN-4.
Therefore, ETAR can be used as a potential therapeutic
drug against dengue viruses [90]. Kiat and colleagues
investigated two cyclohexenyl chalcone derivatives of
Boesenbergia rotunda (L.), 4-hydroxypanduratin A and
panduratin A and showed inhibitory activity of both
compouds against DEN-2 NS3 protease with the Ki
values of 21 and 25 μM, respectively [91]. A series of new
mono- and dialkylated flavanones having NS5 RNA-
dependent RNA polymerase (RdRp) inhibiting activity
named chartaceones A-F (1–6) along with pinocembrin
was identified from Crypotocarya chartacea.Chartaceones
C-F (3–6) which are dialkylated flavanones showed sig-
nificant NS5 RdRp inhibiting activity, with IC(50) ranging
from 1.8 to 4.2 μM [92]. Zandi and colleagues investi-
gated four bioflavanoids (quercetin, daidzein, naringin
and hesperetin) against DEN-2 using Vero cells and
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hibitory actitivty. Thus, there is a need to further investi-
gate these compounds to develop novel inhibitors against
DENV [93]. Three flavonoids; fisetin, naringenin and
rutin were tested against DENV-2 serotype using foci
forming unit reduction assay (FFURA) and quantitative
real-time polymerase chain amplification (qRT-PCR).
After viral adsorption, Fisetin was added that lead to
DENV-2 replication inhibition with a half maximal inhib-
ition concentration (IC50) value of 55 μg/mL and selectiv-
ity index (SI) of 4.49. In Vero cells, rutin and naringenin
did not inhibit DENV-2 replication [94]. Recently, Tang
and colleagues investigated methanolic extracts of
Andrographis paniculata, Citrus limon, Cymbopogon
citratus, Momordica charantia, Ocimum sanctum and
Pelargonium citrosum on DEN-1. Among all the six me-
dicinal plants, A. paniculata showed the most antiviral in-
hibitory effects followed by M. charantia. Thus, these two
plants need further investigations to develop potential
dengue treatment [83].
Conclusion
Dengue infection has emerged as a major health concern
in Southeast Asia, the pacific and America. Dengue virus
has become a serious issue in Pakistan as it has caused
many endemics starting from 1994 to 2011. Developing
tetravalent vaccine against all four dengue serotypes is
quite challenging. To date, there is no licensed vaccine
available for dengue virus. Therefore, there is an urgent
need to develop an alternative solution to combat this
endemic infection. Currently, there are no antiviral com-
pounds available against dengue virus and there is a
need to develop antiviral compounds that can target all
four serotypes of dengue with same efficiency. Dengue
virus enveloped protein is involved in virus cell entry;
NS3 and NS5 are involved in viral replication and other
cellular processes; therefore, these can serve as an im-
portant drug target to combat this life-threatening dis-
ease. Several medicinal plants have been tested against
dengue virus entry and replication; many of them
showed significant inhibitory effects. Nevertheless, it will
be very exciting to see these medicinal plants as poten-
tial DENV inhibitors to progress through clinical devel-
opments and, hopefully, provide dengue patients with
much needed, more effective therapies.
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